Evaluation of the Safety of the Medical Device Simeox®

Inclusion Criteria: * Patient over 18, male or female. * Patient affected by broncho-degenerative disease, chronic obstructive airway disease, cystic fibrosis, idiopathic bronchiectasis, ciliary dyskinesia and/or chronic bronchitis. * Hospitalization for a minimum of five days or a maximum of 8 days. * Bronchial clearance is usually productive. * FVC and / or FEV \<85% predicted, with stable lung function. * Agreement to participate to the study and signature of the informed consent form * Social security coverage. Exclusion Criteria: * Patient infected with bacteria resistant to antibiotics. * Bronchial clearance is not usually productive. * Patient with contra-indication for physiotherapy bronchial clearance. * Patient who received a lung transplant. * Care requires more than 2 sessions of chest physiotherapy daily. * Duration of mechanical ventilation \> 8h/day. * Patient with an episode of hemoptysis during the month before inclusion. * Patient with an episode of pneumothorax during the last month. * Pregnant or lactating women. * Patient with a disability and/or unwillingness to follow protocol requirements. * Patient participating in another clinical study or having tested an experimental drug within 30 days prior to his inclusion in the study. * Patient ( s) with another condition which, according to the investigator , may interfere with the result or conduct of the trial and thus justify their non- inclusion in the study.